<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02133352</url>
  </required_header>
  <id_info>
    <org_study_id>30217</org_study_id>
    <nct_id>NCT02133352</nct_id>
  </id_info>
  <brief_title>Study of Ranolazine in the Treatment of Pulmonary Hypertension Associated With Diastolic Left Ventricular Dysfunction</brief_title>
  <official_title>Proof of Concept Study of Ranolazine in the Treatment of Pulmonary Hypertension Associated With Diastolic Left Ventricular Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center, open-label trial designed to assess the safety and efficacy of&#xD;
      ranolazine (Ranexa) in patients with pulmonary hypertension associated with left ventricular&#xD;
      diastolic dysfunction. All patients will receive active drug. The study includes a screening&#xD;
      period, 6 month treatment period and a follow up period. Eligible patients who provide&#xD;
      informed consent and who meet all inclusion/exclusion criteria will be enrolled in this&#xD;
      study.&#xD;
&#xD;
      There is neither proven therapy for patients with diastolic dysfunction-associated pulmonary&#xD;
      hypertension nor for patients with diastolic dysfunction alone. Ranolazine, an inhibitor of&#xD;
      cardiac repolarization (sodium channels), could represent a new and effective treatment of&#xD;
      this entity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This single center, prospective, open-label trial to assess the safety and efficacy of&#xD;
      ranolazine in subjects with pulmonary hypertension associated with left ventricular diastolic&#xD;
      dysfunction includes a screening period, 6 month treatment period and a follow up period.&#xD;
      Eligible subjects who provide informed consent and who meet all inclusion/exclusion criteria&#xD;
      will be enrolled in this study. All subjects will receive active study drug. There is no&#xD;
      placebo group or use of control subjects. Treating will begin with 500mg twice daily and&#xD;
      increased to 1000mg twice daily as tolerated after 2wks; the tolerated dose will be used for&#xD;
      the remainder of the Treatment Period. Ranolazine will be limited to 500 mg BID in patients&#xD;
      taking moderate inhibitors of CYP3A, including diltiazem, verapamil, aprepitant,&#xD;
      erythromycin, fluconazole, grapefruit juice or grapefruit-containing products. During the&#xD;
      Treatment Period subjects will be provided bottles of study medication to take home.&#xD;
      Throughout the Treatment Period, subjects will return to the clinic for safety and/or&#xD;
      efficacy assessments as well as resupply of Study Medication. Once the Treatment Period is&#xD;
      complete, subjects will return to the clinic for a Follow-Up visit 14 days after the last&#xD;
      dose of study medication, for a final safety assessment. Other therapies or possibly&#xD;
      extension of the ranolazine treatment may be considered after completion of the Treatment&#xD;
      Period at the discretion of the Investigator and will be recorded at the follow-up visit.&#xD;
      Subjects who continue taking ranolazine (as part of there clinical care), will be asked to&#xD;
      return for a 1 year follow up visit for safety and efficacy assessments.&#xD;
&#xD;
      As part of Amendment 2 (submitted November 2013), subjects who continue on ranolazine after&#xD;
      the 6 month treatment period (as part of their clinical care) will be asked to return for&#xD;
      further follow-up testing to better assess the safety and efficacy of the drug. The visit can&#xD;
      be conducted once the patient has been on drug for a total of one year or greater (including&#xD;
      the 6 month treatment period). This would replace the 1 Year follow-up visit for subjects who&#xD;
      have not yet completed the visit and will be an additional visit for those subjects who have.&#xD;
&#xD;
      Subjects can opt to continue on ranolazine regardless of if they agree to complete the Post&#xD;
      Treatment Follow up visit. They do not have to continue with the study after the treatment&#xD;
      phase has been completed in order to stay on ranolazine. The PI and study personnel will&#xD;
      complete the required forms for the Ranexa Connect application if patient wishes to stay on&#xD;
      drug. The Ranexa Connect Program assists patients in obtaining insurance coverage of&#xD;
      ranolazine and financial assistance if needed.&#xD;
&#xD;
      This is a 6 month, single center, prospective, open-label trial. All subjects will be&#xD;
      receiving active treatment, ranolazine at doses approved by the FDA. Subjects will begin&#xD;
      treatment at 500mg twice daily and increase to 1000mg twice daily as tolerated after 2 weeks.&#xD;
      Subjects will take study drug twice daily with or without food. Ranolazine will be limited in&#xD;
      subjects taking CYP3A including diltiazem, verapamil, arprepitant, erythromycin, fluconazole,&#xD;
      grapefruit juice or grapefruit juice containing products. The study will consist of 3&#xD;
      periods: a screening period, a treatment period, and a follow-up period.&#xD;
&#xD;
      Subjects will be asked to come to the study center for 9-10 visits over the course of 6&#xD;
      months. Other therapies or possibly extension of the ranolazine treatment may be considered&#xD;
      after completion of the treatment period at the discretion of the Investigator at the follow&#xD;
      up visit. Subjects who continue on ranolazine after completion of the treatment period of the&#xD;
      study will be asked to return for follow up testing.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in mPAP, PAOP and Pulmonary Vascular Resistance (PVR)</measure>
    <time_frame>180 days</time_frame>
    <description>Assess the percent change in mPAP, PAOP and pulmonary vascular resistance (PVR) by RHC.&#xD;
Additional RHC completed at optional follow up for patients remaining on ranolazine upon completion of 180 day period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Other Hemodynamic Parameters</measure>
    <time_frame>180 days</time_frame>
    <description>Assess % change in other hemodynamic parameters, by RHC, from baseline afeter 180 days of ranolazine.&#xD;
Right atrial pressure (RAP) Systolic pulmonary artery pressure (SPAP) Diastolic pulmonary artery pressure (DPAP) Cardiac output (CO) Cardiac index (CI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 Minute Walk Test (6MWT)</measure>
    <time_frame>180 days</time_frame>
    <description>Assess the change from baseline in 6 minute walk test (6MWT) after 180 days of twice daily ranolazine Optional follow up for some patients also includes 6MWT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cardiac Size and Function</measure>
    <time_frame>180 days</time_frame>
    <description>Assess changes from baseline in measurements of cardiac size and function obtained by MRI after 180 days of twice daily ranolazine.&#xD;
An additional MRI may be completed at optional follow up visit for patients continuing on ranolazine following completion of the 180 day treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Echocardiogram Parameters (LVEF)</measure>
    <time_frame>180 days</time_frame>
    <description>To assess the changes from baseline in echocardiographic parameters (left ventricular geometry and function, LVEF, evidence of diastolic dysfunction, SPAP, right ventricular geometry and function, degree of tricuspid regurgitation) after 180 days of twice daily ranolazine.&#xD;
An additional echo may be completed at optional follow up visit for patients continuing on ranolazine following completion of the 180 day treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BNP Cardiac Biomarker</measure>
    <time_frame>180 days</time_frame>
    <description>Assess the change from baseline in BNP cardiac biomarkers after 180 days of twice daily ranolazine.&#xD;
Cardiac biomarkers may be completed at optional follow up visit for patients continuing on ranolazine following completion of the 180 day treatment period.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Pulmonary Hypertension</condition>
  <condition>Diastolic Left Ventricular Dysfunction</condition>
  <arm_group>
    <arm_group_label>Ranolazine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ranolazine- initiated at 500mg twice daily and increased to 1000mg twice daily as tolerated after 2wks; the tolerated dose will be used for the remainder of the Treatment Period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranolazine</intervention_name>
    <description>Single arm- ranolazine, initiated at 500 mg BID and increased to 1000 mg BID as tolerated</description>
    <arm_group_label>Ranolazine</arm_group_label>
    <other_name>Ranexa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written consent prior to any study procedure&#xD;
&#xD;
          -  Men or women, ages 18 to 75 years&#xD;
&#xD;
          -  Suspicion of Pulmonary Hypertension by echo (RVSP ≥ 50mmHg) or diagnosis of Pulmonary&#xD;
             Hypertension by cardiac cath (mPAP ≥25 mmHg at rest)&#xD;
&#xD;
          -  LVEF ≥50%, (by ECHO, radionuclide imaging, or cardiac cath)&#xD;
&#xD;
          -  6MWT distance ≥150m and ≤450m at both time points within the Screening Period&#xD;
&#xD;
          -  NYHA/WHO functional class II-III&#xD;
&#xD;
          -  RHC measurements on Study Day 1: 1) mean pulmonary artery pressure (MPAP) ≥25 mmHg; 2)&#xD;
             pulmonary artery occlusion pressure (PAOP) ≥18 mmHg and ≤30 mmHg; 3) pulmonary artery&#xD;
             diastolic pressure (PADP) - PAOP ≤10 mmHg&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence or history of any of the following cardiovascular co-morbidities or&#xD;
             conditions: Hypotension at Screening (defined as a resting SBP≤90mmHg). Hypertension&#xD;
             at Screening (defined as resting SBP ≥200mmHg), Unstable cardiovascular disease&#xD;
             including paroxysmal atrial fibrillation or unstable angina, Amyloidosis, hypertrophic&#xD;
             obstructive cardiomyopathy, restrictive cardiomyopathy, or constrictive pericarditis,&#xD;
             History of myocardial infarction, coronary artery bypass graft surgery, or&#xD;
             percutaneous cardiac intervention, Significant valvular heart disease, Cerebrovascular&#xD;
             accident or transient ischemic attack&#xD;
&#xD;
          -  Exercise tolerance limited by non-cardiac causes (exercise-induced asthma, malignancy,&#xD;
             obesity, musculoskeletal disorder).&#xD;
&#xD;
          -  Clinically significant psychiatric, addictive (DSM-IV criteria), neurologic disease or&#xD;
             condition that would compromise his/her ability to give informed consent, participate&#xD;
             fully in this study, or prevent adherence to the protocol&#xD;
&#xD;
          -  Any other condition or co-morbidity that, in the opinion of the Investigator, would&#xD;
             compromise his/her ability to give informed consent, participate fully in this study,&#xD;
             or prevent adherence to the protocol&#xD;
&#xD;
          -  Clinically significant laboratory abnormalities, including: Positive Hep B surface&#xD;
             antigen or Hep C antibody, Positive HIV test within one year of Study Day 1, Serum&#xD;
             alanine aminotransferase (ALT) ≥ 2.0 x ULN, Total bilirubin ≥ 1.2 x ULN (unless&#xD;
             evidence of Gilbert's syndrome). Serum creatinine ≥ 2.5mg/dL (or calculated creatinine&#xD;
             clearance less than or equal to 30mL/min). Hemoglobin less than or equal to 10g/dL&#xD;
             (subject may qualify for the study following diagnosis and treatment of anemia, if the&#xD;
             anemia is due to iron and/or vitamin deficiency).&#xD;
&#xD;
        Patients with moderate or severe hepatic impairment (Child-Pugh Classes B or C) or&#xD;
        requiring hemidialysis.&#xD;
&#xD;
          -  Subject has received any other investigational medication within the 30 days prior to&#xD;
             Screening&#xD;
&#xD;
          -  Prior treatment with ranolazine&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Women of childbearing potential and men without vasectomies who are not using barrier&#xD;
             method of contraception&#xD;
&#xD;
          -  Subject has the presence, or history, of malignancy that required significant medical&#xD;
             intervention within the preceding 3 months and/or is likely to result in death within&#xD;
             the next 2 years (exception of basal cell, non-metastatic squamous cell carcinoma of&#xD;
             the skin, and carcinoma in-situ of the cervix)&#xD;
&#xD;
          -  Treatment for pulmonary hypertension with epoprostenol (Flolan), treprostinil&#xD;
             (Remodulin), iloprost (Ventavis), bosentan (Tracleer), ambrisentan (Letairis),&#xD;
             sildenafil (Revatio), tadalafil (Adcirca). The use of sildenafil, tadalafil, or&#xD;
             vardenafil is prohibited for any reason within 7 days of hemodynamic assessments on&#xD;
             Days 1 and 180).&#xD;
&#xD;
          -  Patients with QTc &gt; 500 msec at baseline&#xD;
&#xD;
          -  Treatment with potent CYP3A inhibitors, including ketoconazole, itraconazonle,&#xD;
             clarithromycin, nefazodone, nelfinavir, indinavir, &amp; saquinavir&#xD;
&#xD;
          -  Treatment with CYP3A inducers, including rifampin, rifabutin, rifapentin,&#xD;
             phenobarbital, phenytoin, carbamazepine, and St. John's wort.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harrison Farber, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boston University Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>May 6, 2014</study_first_submitted>
  <study_first_submitted_qc>May 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2014</study_first_posted>
  <results_first_submitted>February 1, 2016</results_first_submitted>
  <results_first_submitted_qc>May 15, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 17, 2017</results_first_posted>
  <last_update_submitted>May 15, 2017</last_update_submitted>
  <last_update_submitted_qc>May 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pulmonary hypertension</keyword>
  <keyword>diastolic dyfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Ventricular Dysfunction</mesh_term>
    <mesh_term>Ventricular Dysfunction, Left</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranolazine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ranolazine</title>
          <description>Ranolazine- initiated at 500mg twice daily and increased to 1000mg twice daily as tolerated after 2wks; the tolerated dose will be used for the remainder of the Treatment Period.&#xD;
Ranolazine: open label/Single arm- ranolazine, initiated at 500 mg BID and increased to 1000 mg BID as tolerated</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Main Study (180 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Longer Term Extension</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>4 of the initial 10 subjects agreed/cons</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ranolazine</title>
          <description>Ranolazine- initiated at 500mg twice daily and increased to 1000mg twice daily as tolerated after 2wks; the tolerated dose will be used for the remainder of the Treatment Period.&#xD;
Ranolazine: Single arm- ranolazine, initiated at 500 mg BID and increased to 1000 mg BID as tolerated</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.8" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in mPAP, PAOP and Pulmonary Vascular Resistance (PVR)</title>
        <description>Assess the percent change in mPAP, PAOP and pulmonary vascular resistance (PVR) by RHC.&#xD;
Additional RHC completed at optional follow up for patients remaining on ranolazine upon completion of 180 day period.</description>
        <time_frame>180 days</time_frame>
        <population>We hypothesize that patients with pulmonary hypertension associated with diastolic left ventricular dysfunction treated with Ranolazine (initiated at 500 mg twice daily and increased to 1000mg twice daily) would have improved hemodynamic parameters, functional capacity and exercise tolerance compared to baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Ranolazine</title>
            <description>Ranolazine- initiated at 500mg twice daily and increased to 1000mg twice daily as tolerated after 2wks; the tolerated dose will be used for the remainder of the Treatment Period.&#xD;
Ranolazine: open label/Single arm- ranolazine, initiated at 500 mg BID and increased to 1000 mg BID as tolerated</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in mPAP, PAOP and Pulmonary Vascular Resistance (PVR)</title>
          <description>Assess the percent change in mPAP, PAOP and pulmonary vascular resistance (PVR) by RHC.&#xD;
Additional RHC completed at optional follow up for patients remaining on ranolazine upon completion of 180 day period.</description>
          <population>We hypothesize that patients with pulmonary hypertension associated with diastolic left ventricular dysfunction treated with Ranolazine (initiated at 500 mg twice daily and increased to 1000mg twice daily) would have improved hemodynamic parameters, functional capacity and exercise tolerance compared to baseline.</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>% Change in mPAP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21" spread="7.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% Change in PAOP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39" spread="7.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% Change in PVR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.0" spread="153.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Other Hemodynamic Parameters</title>
        <description>Assess % change in other hemodynamic parameters, by RHC, from baseline afeter 180 days of ranolazine.&#xD;
Right atrial pressure (RAP) Systolic pulmonary artery pressure (SPAP) Diastolic pulmonary artery pressure (DPAP) Cardiac output (CO) Cardiac index (CI)</description>
        <time_frame>180 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ranolazine</title>
            <description>Ranolazine- initiated at 500mg twice daily and increased to 1000mg twice daily as tolerated after 2wks; the tolerated dose will be used for the remainder of the Treatment Period.&#xD;
Ranolazine: open label/Single arm- ranolazine, initiated at 500 mg BID and increased to 1000 mg BID as tolerated</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Other Hemodynamic Parameters</title>
          <description>Assess % change in other hemodynamic parameters, by RHC, from baseline afeter 180 days of ranolazine.&#xD;
Right atrial pressure (RAP) Systolic pulmonary artery pressure (SPAP) Diastolic pulmonary artery pressure (DPAP) Cardiac output (CO) Cardiac index (CI)</description>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RAP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-56" spread="4.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SPAP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12" spread="11.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DPAP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33" spread="5.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CO</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22" spread="1.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>6 Minute Walk Test (6MWT)</title>
        <description>Assess the change from baseline in 6 minute walk test (6MWT) after 180 days of twice daily ranolazine Optional follow up for some patients also includes 6MWT.</description>
        <time_frame>180 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ranolazine</title>
            <description>Ranolazine- initiated at 500mg twice daily and increased to 1000mg twice daily as tolerated after 2wks; the tolerated dose will be used for the remainder of the Treatment Period.&#xD;
Ranolazine: open label/Single arm- ranolazine, initiated at 500 mg BID and increased to 1000 mg BID as tolerated</description>
          </group>
        </group_list>
        <measure>
          <title>6 Minute Walk Test (6MWT)</title>
          <description>Assess the change from baseline in 6 minute walk test (6MWT) after 180 days of twice daily ranolazine Optional follow up for some patients also includes 6MWT.</description>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.7" spread="35.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Cardiac Size and Function</title>
        <description>Assess changes from baseline in measurements of cardiac size and function obtained by MRI after 180 days of twice daily ranolazine.&#xD;
An additional MRI may be completed at optional follow up visit for patients continuing on ranolazine following completion of the 180 day treatment period.</description>
        <time_frame>180 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ranolazine</title>
            <description>Ranolazine- initiated at 500mg twice daily and increased to 1000mg twice daily as tolerated after 2wks; the tolerated dose will be used for the remainder of the Treatment Period.&#xD;
Ranolazine: open label/Single arm- ranolazine, initiated at 500 mg BID and increased to 1000 mg BID as tolerated</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cardiac Size and Function</title>
          <description>Assess changes from baseline in measurements of cardiac size and function obtained by MRI after 180 days of twice daily ranolazine.&#xD;
An additional MRI may be completed at optional follow up visit for patients continuing on ranolazine following completion of the 180 day treatment period.</description>
          <units>% ejection fraction</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RVEF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread=".88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LVEF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" spread=".2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Echocardiogram Parameters (LVEF)</title>
        <description>To assess the changes from baseline in echocardiographic parameters (left ventricular geometry and function, LVEF, evidence of diastolic dysfunction, SPAP, right ventricular geometry and function, degree of tricuspid regurgitation) after 180 days of twice daily ranolazine.&#xD;
An additional echo may be completed at optional follow up visit for patients continuing on ranolazine following completion of the 180 day treatment period.</description>
        <time_frame>180 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ranolazine</title>
            <description>Ranolazine- initiated at 500mg twice daily and increased to 1000mg twice daily as tolerated after 2wks; the tolerated dose will be used for the remainder of the Treatment Period.&#xD;
Ranolazine: open label/Single arm- ranolazine, initiated at 500 mg BID and increased to 1000 mg BID as tolerated</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Echocardiogram Parameters (LVEF)</title>
          <description>To assess the changes from baseline in echocardiographic parameters (left ventricular geometry and function, LVEF, evidence of diastolic dysfunction, SPAP, right ventricular geometry and function, degree of tricuspid regurgitation) after 180 days of twice daily ranolazine.&#xD;
An additional echo may be completed at optional follow up visit for patients continuing on ranolazine following completion of the 180 day treatment period.</description>
          <units>LVEF %</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".67" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in BNP Cardiac Biomarker</title>
        <description>Assess the change from baseline in BNP cardiac biomarkers after 180 days of twice daily ranolazine.&#xD;
Cardiac biomarkers may be completed at optional follow up visit for patients continuing on ranolazine following completion of the 180 day treatment period.</description>
        <time_frame>180 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ranolazine</title>
            <description>Ranolazine- initiated at 500mg twice daily and increased to 1000mg twice daily as tolerated after 2wks; the tolerated dose will be used for the remainder of the Treatment Period.&#xD;
Ranolazine: open label/Single arm- ranolazine, initiated at 500 mg BID and increased to 1000 mg BID as tolerated</description>
          </group>
        </group_list>
        <measure>
          <title>Change in BNP Cardiac Biomarker</title>
          <description>Assess the change from baseline in BNP cardiac biomarkers after 180 days of twice daily ranolazine.&#xD;
Cardiac biomarkers may be completed at optional follow up visit for patients continuing on ranolazine following completion of the 180 day treatment period.</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.1" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>180 Days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ranolazine</title>
          <description>Ranolazine- initiated at 500mg twice daily and increased to 1000mg twice daily as tolerated after 2wks; the tolerated dose will be used for the remainder of the Treatment Period.&#xD;
Ranolazine: Single arm- ranolazine, initiated at 500 mg BID and increased to 1000 mg BID as tolerated</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia with junctional ventricular escapes</sub_title>
                <description>Hospital admission revealing bradycardia with ventricular escapes.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>CHF Exacerbation</sub_title>
                <description>Patient admitted 02Jan2013, resolved 12Jan2013. Unrelated to study drug.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <description>Patient admitted with chest pain on 07APR2013. Not thought to be related to drug.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI bleed</sub_title>
                <description>Patient admitted for GI bleed. Felt to be unrelated to study drug.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>elevated blood sugar</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>increased stomach discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>difficulty concentrating</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>patient fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>common cold</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>lightheadedness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>increased fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>sore throat</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>muscle spasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>buttocks/upper leg pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>thumb pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>worsening foot pain/gout</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>kidney infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>intermittent increased back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>knee pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>increased shortness of breath</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small sample size; not all subjects completed Day 180 assessments</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Kimberly Finch</name_or_title>
      <organization>Boston University</organization>
      <phone>617-638-4475</phone>
      <email>kimtobin@bu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

